Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 17, Issue 12, 1999, Pages 3793-3803

  Witzig, Thomas E ^a   White, Christine A ^a   Wiseman, Gregory A ^a   Gordon, Leo I ^a   Emmanouilides, Christos ^a   Raubitschek, Andrew ^a   Janakiraman, Nalini ^a   Gutheil, John ^a   Schilder, Russell J ^a   Spies, Stewart ^a   Silverman, Daniel H S ^a   Parker, Elizabeth ^a   Grillo López, Antonio J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; YTTRIUM 90; YTTRIUM IBRITUMOMAB TIUXETAN Y 90;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; BACKACHE; BLOOD TOXICITY; CANCER RECURRENCE; CHILL; CLINICAL TRIAL; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPOTENSION; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOLOGY;

EID: 0032761164     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.12.3793     Document Type: Article

References (38)

1. Miller R, Maloney D, Warnke R, et al: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517-522, 1982
2. Nadler L, Stashenko P, Hardy R, et al: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147-3154, 1980
3. Nadler LM, Takvorian T, Botnick L, et al: Anti-B1 monoclonal antibody and complement treatment in autologous bone marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2:427-431, 1984
4. Ritz J, Pesando J, Notis-McConarty J, et al: Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol 125:1506-1514, 1980
5. McLaughlin P, Grillo-López A, Link B, et al: Rituximab chimenc anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
6. McLaughlin P, Grillo-López A, Maloney D, et al: Efficacy controls in long-term follow-up of patients treated with rituximab for relapsed or refractory, low-grade or follicular NHL. Blood 92:414a-415a, 1998 (suppl 1)
7. Eary J, Badger C, Press O, et al: Treatment of B-cell lymphoma with I-131 labeled murine monoclonal antibodies. J Nucl Med 29:757-758, 1988 (abstr)
8. Press O, Farr A, Borroz K, et al: Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 49:4906-4912, 1989
9. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
10. 131-I-anti-B1 (anti-CD20) radioimmunotherapy (RIT) for refractory B-cell lymphoma. Blood 82:332a, 1993 (suppl 1; abstr)
11. Wahl R, Zasadny K, Milik A, et al: 131 I anti-B1 radioimmunotherapy of non-Hodgkin's lymphoma without marrow transplantation: Expanded phase I study results. J Nucl Med 35:101P, 1994 (abstr)
12. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 346:336-340, 1995
13. Scheinberg D, Strand M: Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res 43:265-272, 1983
14. Anderson W. Strand M: Radiolabeled antibody: Iodine versus radiometal chelates. Natl Cancer Inst Monogr 3:149-151, 1987
15. Ward J: Biotechnology and nuclear medicine: Radiology brings biotechnology into the picture to combat cancer. Adv Radiol Sci Professionals 11:24-25, 108, 1998
16. Gates VL, Carey JE, Siegel JA, et al: Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J Nucl Med 39:1230-1236, 1998
17. 111In-labeled monoclonal antibody 96.5. Cancer Res 45:2376-2381, 1985
18. Dillman R, Beauregard J, Ryan K, et al: Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies. NCI Monogr 3:33-36, 1987
19. Lamki LM, Babaian R, Murray JL, et al: The effect of increasing "cold" antibody dose on prostatic cancer metastases detection and on body distribution of PAY-276 monoclonal antibody. J Nucl Med 27:1021, 1986 (abstr)
20. Rosenblum M, Murray J, Haynie T, et al: Pharmacokinetics of 111-In-labeled anti-P97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res 45:2382-2386, 1986
21. Stashenko P, Nadler L, Hardy R, et al: Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678-1685, 1980
22. Knox S, Goris M, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
23. Reff M, Carner K, Chambers K, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
24. Maloney D, Grillo-López A, Bodkin D, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
25. Maloney D, Grillo-López A, White C, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
26. Gribben J, Freedman A, Woo S, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991
27. Horning S, Cheson B, Peterson B, et al: Response criteria and quality assurance of responses in the evaluation of new therapies for patients with low-grade lymphoma. Proc Am Soc Clin Oncol 16:18a, 1997 (abstr)
28. Grillo-López A, Horning S, Cheson B, et al: Development of response criteria for low-grade or follicular lymphomas and application in a 166 patient study. Exp Hematol 25:732, 1997 (abstr)
29. Grillo-López A, Cheson B, Horning S, et al: Response criteria for NHL: Importance of "normal" lymph node size and correlations response. Blood 92:412a, 1998 (suppl 1) (abstr)
30. Wiseman GA, White CA, Witzig TE, et al: Final dosimetry results of IDEC-Y2B8 phase I/II yttrium-90 radioimmunotherapy trial in non-Hodgkin's lymphoma. J Nucl Med 40:64p, 1999 (abstr)
31. Maloney D, Smith B, Appelbaum F: The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 88:637a, 1996 (abstr)
32. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
33. Lundin J, Osterborg A, Brittinger G, et al: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study-European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 16:3257-3263, 1998
34. DeNardo GL, DeNardo SJ, Goldstein DS, et al: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16:3246-3256, 1998
35. Kaminski M, Zasadny K, Francis I, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
36. Kaminski M, Gribbin T, Estes J, et al: I-131 anti-B1 antibody for previously untreated follicular lymphoma (fl): Clinical and molecular remissions. Proc Am Soc Clin Oncol 17:2a, 1998 (abstr 6)
37. Liu S, Early J, Petersdorf S, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131 - labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270-3278, 1998
38. Press O, Eary J, Liu S, et al: A phase I/II trial of high dose iodine 131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphomas. Proc Am Soc Clin Oncol 17:3a, 1998 (abstr)